Kamada Ltd (NASDAQ:KMDA)
| Market Cap | $446.45M+13.3% |
| Revenue (ttm) | $196.87M+12.6% |
| Net Income | $24.95M+22.0% |
| EPS | $0.43+19.2% |
| Shares Out | 57.68M |
| PE Ratio | 17.88 |
| Forward PE | 13.34 |
| Dividend | $0.56(7.24%) |
| Ex-Dividend Date | Nov 19, 2026 |
| Volume | 84,304 |
| Open | $7.73 |
| Previous Close | $7.83 |
| Day's Range | $7.72 - $7.99 |
| 52-Week Range | $6.63 - $9.35 |
| Beta | 0.13 |
| Analysts | Buy |
| Price Target | $14.00(+80.88%) |
| Earnings Date | Mar 10, 2027 |
About KMDA
Kamada Ltd. is a biopharmaceutical firm focused on developing, manufacturing, and distributing protein therapeutics derived from human plasma. The company operates through two core business areas: its proprietary product segment and its distribution division. Its own manufactured portfolio includes KAMRAB/KEDRAB for rabies prevention, CYTOGAM to prevent cytomegalovirus disease in transplant recipients, WINRHO SDF for immune thrombocytopenic purpura and Rhesus (Rh) isoimmunization, HEPAGAM B for hepatitis B recurrence prevention following liver transplants and for post-exposure prophylaxis, VARIZIG for post-exposure chickenpox prophylaxis, and GLASSIA for intravenous alpha-1 antitrypsin deficiency (AATD). Kamada also produces KamRho (D) for the prophylaxis of hemolytic disease of newborns and immune thrombocytopenic purpura, along with a specific antiserum for Vipera palaestinae and Echis coloratus snake bites. Additionally, the company distributes a wide array of third-party pharmaceutical products, encompassing treatments like BRAMITOB for chronic pulmonary infections, FOSTER for asthma, PROVOCHOLINE for diagnosing bronchial airway hyperactivity, and specialized therapies such as IVIG for immunodeficiency, VARITECT for chickenpox and zoster herpes, and various factors for hemophilia A and B, among numerous others for conditions like hepatitis B, cytomegalovirus, angioedema, Japanese encephalitis, and prostate cancer. Kamada markets its offerings in the United States through strategic partners and internationally via a network of distributors. The company maintains significant collaborations with Takeda Pharmaceuticals Company Limited, PARI GmbH, and Kedrion Biopharma. Established in 1990, Kamada Ltd. is headquartered in Rehovot, Israel.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Mar 10, 2027Earnings report
$KMDA stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in KMDA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by KMDA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
KMDA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
KMDA Revenue by Segment or Geography
Source: SEC EDGAR (10-Q/10-K)
U.S. Patents
New KMDA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to KMDA from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in KMDA
| IZRLARK Israel Innovative Technology ETF | $592.62K |
| DISVDimensional - International Small Cap Value ETF | $432.80K |
| DFISDimensional - International Small Cap ETF | $325.98K |
| DFICDimensional - International Core Equity 2 ETF | $280.33K |
| AIMSAcuitas Small Cap Active ETF | $184.26K |
| DFAXDimensional World ex U.S. Core Equity 2 ETF | $103.66K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from KMDA’s recent data — informational, not investment advice
What’s Behind the Score
News check: Record 9-month revenue, raised 2026 guidance, surpassed Q3 estimates, projected double-digit 2027 growth, and raised dividend signal strong financial performance.
Recent Insider Activity
Insider Score Trend Over Time
+0.0 since Sep 12Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
